Moss Genomics (MOSS) 주식 개요는 캐나다에서 개인 맞춤형 건강, 노화 방지 및 웰니스 제품을 제조 및 판매하는 회사입니다. 자세히 보기MOSS 펀더멘털 분석스노우플레이크 점수가치 평가0/6미래 성장0/6과거 실적0/6재무 건전성0/6배당0/6위험 분석재무 데이터를 보고하지 않았습니다.의미 있는 시가총액이 없습니다(CA$2M)주식은 유동성이 매우 낮습니다모든 위험 점검 보기MOSS Community Fair Values Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.Your Fair ValueCA$Current PriceCA$0.03해당 없음내재 할인율Est. Revenue$PastFuture012016201920222025202620282031Revenue CA$1.0Earnings CA$0.2AdvancedSet Fair ValueView all narrativesMoss Genomics Inc. 경쟁사Psyence GroupSymbol: CNSX:PSYGMarket cap: CA$1.9mCytophage TechnologiesSymbol: TSXV:CYTOMarket cap: CA$1.7mNeural TherapeuticsSymbol: CNSX:NURLMarket cap: CA$2.5mEntheon BiomedicalSymbol: CNSX:ENBIMarket cap: CA$1.4m가격 이력 및 성과Moss Genomics 주가의 최고가, 최저가 및 변동 요약과거 주가현재 주가CA$0.0352주 최고가CA$0.2052주 최저가CA$0.005베타01개월 변동0%3개월 변동-14.29%1년 변동-79.31%3년 변동-84.62%5년 변동n/aIPO 이후 변동-85.19%최근 뉴스 및 업데이트공시 • Nov 13Moss Genomics Inc. announced that it has received CAD 0.1 million in fundingMoss Genomics Inc. announces that it has closed a non-brokered private placement of 555,555 common shares at CAD 0.18 per share for gross proceeds of CAD 100,000 on November 12, 2025. No finder’s fees were paid.공시 • Aug 27Moss Genomics Inc., Annual General Meeting, Sep 29, 2025Moss Genomics Inc., Annual General Meeting, Sep 29, 2025.New Risk • May 17New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 29% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks No financial data reported. Share price has been highly volatile over the past 3 months (74% average weekly change). Market cap is less than US$10m (CA$4.62m market cap, or US$3.30m). Minor Risk Shareholders have been diluted in the past year (29% increase in shares outstanding).공시 • Feb 27+ 1 more updateMoss Genomics Inc. Appoints Michal Goldstein as its Fractional Chief Financial OfficerMoss Genomics Inc. announced the appointment of Michal "Mickey" Goldstein as its new fractional Chief Financial Officer (CFO). Moss Genomics is confident that Ms. Goldstein's extensive financial expertise and leadership experience will be instrumental in supporting the Company's continued expansion and operational efficiency.공시 • Feb 04Moss Genomics Inc. announced that it expects to receive CAD 0.36 million in fundingMoss Genomics Inc. announced a non-brokered private placement on February 3, 2025. The company will issue 2,000,000 common shares at price of CAD 0.18 per share for aggregate proceeds of up to CAD 360,000. The Offering may close in one or more tranches and is subject to the approval of the Canadian Securities Exchange. All securities issued under the Offering will be subject to a statutory hold period expiring four months plus one day from the date of issuance.공시 • Dec 25Moss Genomics Inc. announced that it expects to receive CAD 0.25 million in fundingMoss Genomics Inc. announced a non-brokered private placement that it will issue up to 2,500,000 common shares of the company at an issue price of CAD 0.10 per share for the gross proceeds of up to CAD 250,000 on December 24, 2024. The Offering may close in one or more tranches and is subject to the approval of the Canadian Securities Exchange. All securities issued under the Offering will be subject to a statutory hold period expiring four months plus one day from the date of issuance. Additionally, the Company may pay finders' fees in connection with the Offering in accordance with the policies of the Exchange. The Company also announces that it has granted a total of 600,000 stock options to certain directors, officers and consultants of the Company. The options are each exercisable to purchase one common share of the Company at an exercise price of CAD 0.10 for a period of 5 years.더 많은 업데이트 보기Recent updates공시 • Nov 13Moss Genomics Inc. announced that it has received CAD 0.1 million in fundingMoss Genomics Inc. announces that it has closed a non-brokered private placement of 555,555 common shares at CAD 0.18 per share for gross proceeds of CAD 100,000 on November 12, 2025. No finder’s fees were paid.공시 • Aug 27Moss Genomics Inc., Annual General Meeting, Sep 29, 2025Moss Genomics Inc., Annual General Meeting, Sep 29, 2025.New Risk • May 17New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 29% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks No financial data reported. Share price has been highly volatile over the past 3 months (74% average weekly change). Market cap is less than US$10m (CA$4.62m market cap, or US$3.30m). Minor Risk Shareholders have been diluted in the past year (29% increase in shares outstanding).공시 • Feb 27+ 1 more updateMoss Genomics Inc. Appoints Michal Goldstein as its Fractional Chief Financial OfficerMoss Genomics Inc. announced the appointment of Michal "Mickey" Goldstein as its new fractional Chief Financial Officer (CFO). Moss Genomics is confident that Ms. Goldstein's extensive financial expertise and leadership experience will be instrumental in supporting the Company's continued expansion and operational efficiency.공시 • Feb 04Moss Genomics Inc. announced that it expects to receive CAD 0.36 million in fundingMoss Genomics Inc. announced a non-brokered private placement on February 3, 2025. The company will issue 2,000,000 common shares at price of CAD 0.18 per share for aggregate proceeds of up to CAD 360,000. The Offering may close in one or more tranches and is subject to the approval of the Canadian Securities Exchange. All securities issued under the Offering will be subject to a statutory hold period expiring four months plus one day from the date of issuance.공시 • Dec 25Moss Genomics Inc. announced that it expects to receive CAD 0.25 million in fundingMoss Genomics Inc. announced a non-brokered private placement that it will issue up to 2,500,000 common shares of the company at an issue price of CAD 0.10 per share for the gross proceeds of up to CAD 250,000 on December 24, 2024. The Offering may close in one or more tranches and is subject to the approval of the Canadian Securities Exchange. All securities issued under the Offering will be subject to a statutory hold period expiring four months plus one day from the date of issuance. Additionally, the Company may pay finders' fees in connection with the Offering in accordance with the policies of the Exchange. The Company also announces that it has granted a total of 600,000 stock options to certain directors, officers and consultants of the Company. The options are each exercisable to purchase one common share of the Company at an exercise price of CAD 0.10 for a period of 5 years.공시 • May 31Moss Genomics Inc., Annual General Meeting, Jul 25, 2024Moss Genomics Inc., Annual General Meeting, Jul 25, 2024.Board Change • May 09Less than half of directors are independentFollowing the recent departure of a director, there is only 1 independent director on the board. The company's board is composed of: 1 independent director. 3 non-independent directors. Non-Independent Director Min Seob Lee was the last independent director to join the board, commencing their role in 2022. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.Board Change • Apr 17Less than half of directors are independentFollowing the recent departure of a director, there is only 1 independent director on the board. The company's board is composed of: 1 independent director. 3 non-independent directors. Non-Independent Director Min Seob Lee was the last independent director to join the board, commencing their role in 2022. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.Board Change • Mar 18Less than half of directors are independentFollowing the recent departure of a director, there is only 1 independent director on the board. The company's board is composed of: 1 independent director. 3 non-independent directors. Non-Independent Director Min Seob Lee was the last independent director to join the board, commencing their role in 2022. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.Board Change • Nov 30Less than half of directors are independentFollowing the recent departure of a director, there is only 1 independent director on the board. The company's board is composed of: 1 independent director. 3 non-independent directors. Non-Independent Director Min Seob Lee was the last independent director to join the board, commencing their role in 2022. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.Board Change • Nov 13Less than half of directors are independentFollowing the recent departure of a director, there is only 1 independent director on the board. The company's board is composed of: 1 independent director. 3 non-independent directors. Non-Independent Director Min Seob Lee was the last independent director to join the board, commencing their role in 2022. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.Board Change • Oct 25Less than half of directors are independentFollowing the recent departure of a director, there is only 1 independent director on the board. The company's board is composed of: 1 independent director. 3 non-independent directors. Non-Independent Director Min Seob Lee was the last independent director to join the board, commencing their role in 2022. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.공시 • Sep 21Moss Genomics Inc. Expects to Launch Its 90-Second Urine Test and Smartphone App in December 2023Moss Genomics Inc. announced that it expects to launch its 90-second urine test and accompanying smartphone app in December 2023. This revolutionary product is set to transform the way individuals monitor their health and detect potential medical conditions, offering quick, accurate, and convenient results at their fingertips. Moss 90-second urine test utilizes cutting-edge technology to provide rapid and accurate results. By simply collecting a small urine sample, users will receive comprehensive health insights within just 90 seconds. This breakthrough technology eliminates the need for time-consuming laboratory tests. Accompanying the urine test will be a user-friendly smartphone app, providing users with a comprehensive analysis of their health data. Through the app, users will be able to track their health trends, set personalized health goals, and receive real-time notifications and recommendations based on their test results. The app will also offer a secure platform for users to share their data with healthcare professionals, enabling remote monitoring and personalized medical advice. The Moss team, alongside its partners, have worked to ensure the accuracy and reliability of the urine test and app. Extensive testing has been conducted to validate the technology's effectiveness. The results have been overwhelmingly positive, demonstrating the test's ability to detect a wide range of health conditions with high accuracy. The launch of the 90-second urine test and smartphone app is scheduled for December 2023.Board Change • Jul 24Less than half of directors are independentFollowing the recent departure of a director, there is only 1 independent director on the board. The company's board is composed of: 1 independent director. 3 non-independent directors. Non-Independent Director Min Seob Lee was the last independent director to join the board, commencing their role in 2022. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.공시 • Jun 17Moss Genomics Inc. Introduces Diet and Vitamin ReportsMoss Genomics Inc. announced the introduction of its diet and vitamin reports which can be ordered directly to your home via its online platform. Up to 80 million genetic variants are analyzed to provide the most insightful information concerning dietary needs and vitamin deficiencies. its diet reports provide information about celiac, alcohol sensitivity, sweet tooth, caffeine related anxiety, hunger, food allergies, response to carbohydrates, bitter taste sensitivity and lactose intolerance. its Reports highlight micronutrient deficiencies and requirements such as Riboflavin, MTHFR (folate), Vitamin B12, Vitamin C, Vitamin D and Iron. These Reports give customers the opportunity to further explore and understand their genetic data. Moss customers can enjoy a comprehensive suite of genetic reports available in its online shop. Moss has created an online healthcare and technology platform integrating labs, services, and products in a shared economy. Moss provides comprehensive and affordable, at-home genetic and microbiome testing paired with personalized wellness reports and offerings to promote total gut, mind, and body health. The Company's services include health reports, personalized food and nutrition recommendations, and a social media platform that allows customers to form communities based on their specific health needs.Board Change • Jun 01Less than half of directors are independentFollowing the recent departure of a director, there is only 1 independent director on the board. The company's board is composed of: 1 independent director. 3 non-independent directors. Non-Independent Director Min Seob Lee was the last independent director to join the board, commencing their role in 2022. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.Board Change • Mar 02Less than half of directors are independentFollowing the recent departure of a director, there is only 1 independent director on the board. The company's board is composed of: 1 independent director. 3 non-independent directors. Non-Independent Director Min Seob Lee was the last independent director to join the board, commencing their role in 2022. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.Board Change • Feb 01Less than half of directors are independentFollowing the recent departure of a director, there is only 1 independent director on the board. The company's board is composed of: 1 independent director. 3 non-independent directors. Non-Independent Director Min Seob Lee was the last independent director to join the board, commencing their role in 2022. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.주주 수익률MOSSCA BiotechsCA 시장7D0%7.8%2.5%1Y-79.3%17.6%33.9%전체 주주 수익률 보기수익률 대 산업: MOSS은 지난 1년 동안 17.6%의 수익을 기록한 Canadian Biotechs 산업보다 저조한 성과를 냈습니다.수익률 대 시장: MOSS은 지난 1년 동안 33.9%를 기록한 Canadian 시장보다 저조한 성과를 냈습니다.주가 변동성Is MOSS's price volatile compared to industry and market?MOSS volatilityMOSS Average Weekly Movementn/aBiotechs Industry Average Movement11.2%Market Average Movement10.2%10% most volatile stocks in CA Market17.7%10% least volatile stocks in CA Market3.9%안정적인 주가: MOSS의 주가는 지난 3개월 동안 Canadian 시장보다 변동성이 컸습니다.시간에 따른 변동성: Insufficient data to determine MOSS의 변동성 변화를 판단할 수 없습니다.회사 소개설립직원 수CEO웹사이트2018n/aJack Liuwww.mossgenomics.com는 캐나다에서 개인 맞춤형 건강, 노화 방지 및 웰니스 제품을 제조 및 판매합니다. 이 회사는 이전에 누 캠프 캐피털 주식회사로 알려졌으며 2021년 7월에 모스 지노믹스로 사명을 변경했습니다. 는 2018년에 설립되었으며 캐나다 밴쿠버에 본사를 두고 있습니다.더 보기Moss Genomics Inc. 기초 지표 요약Moss Genomics의 순이익과 매출은 시가총액과 어떻게 비교됩니까?MOSS 기초 통계시가총액CA$1.90m순이익 (TTM)CA$0매출 (TTM)n/an/a주가수익비율(P/E)n/a주가매출비율(P/S)MOSS는 고평가되어 있습니까?공정 가치 및 평가 분석 보기순이익 및 매출최근 실적 보고서(TTM)의 주요 수익성 지표MOSS 손익계산서 (TTM)매출CA$0매출원가CA$0총이익CA$0기타 비용CA$0순이익CA$0최근 보고된 실적해당 없음다음 실적 발표일해당 없음주당순이익(EPS)0총이익률0.00%순이익률0.00%부채/자본 비율0.0%MOSS의 장기 실적은 어땠습니까?과거 실적 및 비교 보기View Valuation기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2026/05/26 20:31종가2026/05/19 00:00수익N/A연간 수익N/A데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스Moss Genomics Inc.는 0명의 분석가가 다루고 있습니다. 이 중 0명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.
공시 • Nov 13Moss Genomics Inc. announced that it has received CAD 0.1 million in fundingMoss Genomics Inc. announces that it has closed a non-brokered private placement of 555,555 common shares at CAD 0.18 per share for gross proceeds of CAD 100,000 on November 12, 2025. No finder’s fees were paid.
공시 • Aug 27Moss Genomics Inc., Annual General Meeting, Sep 29, 2025Moss Genomics Inc., Annual General Meeting, Sep 29, 2025.
New Risk • May 17New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 29% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks No financial data reported. Share price has been highly volatile over the past 3 months (74% average weekly change). Market cap is less than US$10m (CA$4.62m market cap, or US$3.30m). Minor Risk Shareholders have been diluted in the past year (29% increase in shares outstanding).
공시 • Feb 27+ 1 more updateMoss Genomics Inc. Appoints Michal Goldstein as its Fractional Chief Financial OfficerMoss Genomics Inc. announced the appointment of Michal "Mickey" Goldstein as its new fractional Chief Financial Officer (CFO). Moss Genomics is confident that Ms. Goldstein's extensive financial expertise and leadership experience will be instrumental in supporting the Company's continued expansion and operational efficiency.
공시 • Feb 04Moss Genomics Inc. announced that it expects to receive CAD 0.36 million in fundingMoss Genomics Inc. announced a non-brokered private placement on February 3, 2025. The company will issue 2,000,000 common shares at price of CAD 0.18 per share for aggregate proceeds of up to CAD 360,000. The Offering may close in one or more tranches and is subject to the approval of the Canadian Securities Exchange. All securities issued under the Offering will be subject to a statutory hold period expiring four months plus one day from the date of issuance.
공시 • Dec 25Moss Genomics Inc. announced that it expects to receive CAD 0.25 million in fundingMoss Genomics Inc. announced a non-brokered private placement that it will issue up to 2,500,000 common shares of the company at an issue price of CAD 0.10 per share for the gross proceeds of up to CAD 250,000 on December 24, 2024. The Offering may close in one or more tranches and is subject to the approval of the Canadian Securities Exchange. All securities issued under the Offering will be subject to a statutory hold period expiring four months plus one day from the date of issuance. Additionally, the Company may pay finders' fees in connection with the Offering in accordance with the policies of the Exchange. The Company also announces that it has granted a total of 600,000 stock options to certain directors, officers and consultants of the Company. The options are each exercisable to purchase one common share of the Company at an exercise price of CAD 0.10 for a period of 5 years.
공시 • Nov 13Moss Genomics Inc. announced that it has received CAD 0.1 million in fundingMoss Genomics Inc. announces that it has closed a non-brokered private placement of 555,555 common shares at CAD 0.18 per share for gross proceeds of CAD 100,000 on November 12, 2025. No finder’s fees were paid.
공시 • Aug 27Moss Genomics Inc., Annual General Meeting, Sep 29, 2025Moss Genomics Inc., Annual General Meeting, Sep 29, 2025.
New Risk • May 17New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 29% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks No financial data reported. Share price has been highly volatile over the past 3 months (74% average weekly change). Market cap is less than US$10m (CA$4.62m market cap, or US$3.30m). Minor Risk Shareholders have been diluted in the past year (29% increase in shares outstanding).
공시 • Feb 27+ 1 more updateMoss Genomics Inc. Appoints Michal Goldstein as its Fractional Chief Financial OfficerMoss Genomics Inc. announced the appointment of Michal "Mickey" Goldstein as its new fractional Chief Financial Officer (CFO). Moss Genomics is confident that Ms. Goldstein's extensive financial expertise and leadership experience will be instrumental in supporting the Company's continued expansion and operational efficiency.
공시 • Feb 04Moss Genomics Inc. announced that it expects to receive CAD 0.36 million in fundingMoss Genomics Inc. announced a non-brokered private placement on February 3, 2025. The company will issue 2,000,000 common shares at price of CAD 0.18 per share for aggregate proceeds of up to CAD 360,000. The Offering may close in one or more tranches and is subject to the approval of the Canadian Securities Exchange. All securities issued under the Offering will be subject to a statutory hold period expiring four months plus one day from the date of issuance.
공시 • Dec 25Moss Genomics Inc. announced that it expects to receive CAD 0.25 million in fundingMoss Genomics Inc. announced a non-brokered private placement that it will issue up to 2,500,000 common shares of the company at an issue price of CAD 0.10 per share for the gross proceeds of up to CAD 250,000 on December 24, 2024. The Offering may close in one or more tranches and is subject to the approval of the Canadian Securities Exchange. All securities issued under the Offering will be subject to a statutory hold period expiring four months plus one day from the date of issuance. Additionally, the Company may pay finders' fees in connection with the Offering in accordance with the policies of the Exchange. The Company also announces that it has granted a total of 600,000 stock options to certain directors, officers and consultants of the Company. The options are each exercisable to purchase one common share of the Company at an exercise price of CAD 0.10 for a period of 5 years.
공시 • May 31Moss Genomics Inc., Annual General Meeting, Jul 25, 2024Moss Genomics Inc., Annual General Meeting, Jul 25, 2024.
Board Change • May 09Less than half of directors are independentFollowing the recent departure of a director, there is only 1 independent director on the board. The company's board is composed of: 1 independent director. 3 non-independent directors. Non-Independent Director Min Seob Lee was the last independent director to join the board, commencing their role in 2022. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.
Board Change • Apr 17Less than half of directors are independentFollowing the recent departure of a director, there is only 1 independent director on the board. The company's board is composed of: 1 independent director. 3 non-independent directors. Non-Independent Director Min Seob Lee was the last independent director to join the board, commencing their role in 2022. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.
Board Change • Mar 18Less than half of directors are independentFollowing the recent departure of a director, there is only 1 independent director on the board. The company's board is composed of: 1 independent director. 3 non-independent directors. Non-Independent Director Min Seob Lee was the last independent director to join the board, commencing their role in 2022. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.
Board Change • Nov 30Less than half of directors are independentFollowing the recent departure of a director, there is only 1 independent director on the board. The company's board is composed of: 1 independent director. 3 non-independent directors. Non-Independent Director Min Seob Lee was the last independent director to join the board, commencing their role in 2022. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.
Board Change • Nov 13Less than half of directors are independentFollowing the recent departure of a director, there is only 1 independent director on the board. The company's board is composed of: 1 independent director. 3 non-independent directors. Non-Independent Director Min Seob Lee was the last independent director to join the board, commencing their role in 2022. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.
Board Change • Oct 25Less than half of directors are independentFollowing the recent departure of a director, there is only 1 independent director on the board. The company's board is composed of: 1 independent director. 3 non-independent directors. Non-Independent Director Min Seob Lee was the last independent director to join the board, commencing their role in 2022. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.
공시 • Sep 21Moss Genomics Inc. Expects to Launch Its 90-Second Urine Test and Smartphone App in December 2023Moss Genomics Inc. announced that it expects to launch its 90-second urine test and accompanying smartphone app in December 2023. This revolutionary product is set to transform the way individuals monitor their health and detect potential medical conditions, offering quick, accurate, and convenient results at their fingertips. Moss 90-second urine test utilizes cutting-edge technology to provide rapid and accurate results. By simply collecting a small urine sample, users will receive comprehensive health insights within just 90 seconds. This breakthrough technology eliminates the need for time-consuming laboratory tests. Accompanying the urine test will be a user-friendly smartphone app, providing users with a comprehensive analysis of their health data. Through the app, users will be able to track their health trends, set personalized health goals, and receive real-time notifications and recommendations based on their test results. The app will also offer a secure platform for users to share their data with healthcare professionals, enabling remote monitoring and personalized medical advice. The Moss team, alongside its partners, have worked to ensure the accuracy and reliability of the urine test and app. Extensive testing has been conducted to validate the technology's effectiveness. The results have been overwhelmingly positive, demonstrating the test's ability to detect a wide range of health conditions with high accuracy. The launch of the 90-second urine test and smartphone app is scheduled for December 2023.
Board Change • Jul 24Less than half of directors are independentFollowing the recent departure of a director, there is only 1 independent director on the board. The company's board is composed of: 1 independent director. 3 non-independent directors. Non-Independent Director Min Seob Lee was the last independent director to join the board, commencing their role in 2022. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.
공시 • Jun 17Moss Genomics Inc. Introduces Diet and Vitamin ReportsMoss Genomics Inc. announced the introduction of its diet and vitamin reports which can be ordered directly to your home via its online platform. Up to 80 million genetic variants are analyzed to provide the most insightful information concerning dietary needs and vitamin deficiencies. its diet reports provide information about celiac, alcohol sensitivity, sweet tooth, caffeine related anxiety, hunger, food allergies, response to carbohydrates, bitter taste sensitivity and lactose intolerance. its Reports highlight micronutrient deficiencies and requirements such as Riboflavin, MTHFR (folate), Vitamin B12, Vitamin C, Vitamin D and Iron. These Reports give customers the opportunity to further explore and understand their genetic data. Moss customers can enjoy a comprehensive suite of genetic reports available in its online shop. Moss has created an online healthcare and technology platform integrating labs, services, and products in a shared economy. Moss provides comprehensive and affordable, at-home genetic and microbiome testing paired with personalized wellness reports and offerings to promote total gut, mind, and body health. The Company's services include health reports, personalized food and nutrition recommendations, and a social media platform that allows customers to form communities based on their specific health needs.
Board Change • Jun 01Less than half of directors are independentFollowing the recent departure of a director, there is only 1 independent director on the board. The company's board is composed of: 1 independent director. 3 non-independent directors. Non-Independent Director Min Seob Lee was the last independent director to join the board, commencing their role in 2022. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.
Board Change • Mar 02Less than half of directors are independentFollowing the recent departure of a director, there is only 1 independent director on the board. The company's board is composed of: 1 independent director. 3 non-independent directors. Non-Independent Director Min Seob Lee was the last independent director to join the board, commencing their role in 2022. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.
Board Change • Feb 01Less than half of directors are independentFollowing the recent departure of a director, there is only 1 independent director on the board. The company's board is composed of: 1 independent director. 3 non-independent directors. Non-Independent Director Min Seob Lee was the last independent director to join the board, commencing their role in 2022. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.
